Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
about
Current concepts in thrombotic thrombocytopenic purpuraPathogenesis of thrombotic microangiopathiesCurrent understanding of the pathophysiology of thrombotic thrombocytopenic purpura.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Thrombotic thrombocytopenic purpura: survival by "giving a dam"The kidney in thrombotic thrombocytopenic purpura.Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.ADAMTS13 gene mutations in children with hemolytic uremic syndrome.Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.Reduced ADAMTS13 activity is associated with an ADAMTS13 SNP, fever and microparticles in a malaria-like modelOn the versatility of von Willebrand factorThe ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura.Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability.mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation
P2860
Q24656680-6F6235F0-2B02-40DD-AB9D-4626160AD558Q24658043-55E7A0B1-2BD3-4AE8-A6CE-B460DD208E58Q33333785-C5F184B5-2DFB-4EEC-9C43-92C02EAC2DECQ33369765-8441FB2B-AF82-40E3-99EE-57110F69B75CQ33373067-9FBBC8B7-3A8E-4CFE-B325-093733D6988EQ33378755-107D9866-FF6A-4A33-97D7-6C1F007BE6A5Q33382110-594645BB-975E-45C9-BD92-62B65F8943D3Q33394897-8D35D115-A570-4872-A7B2-982F7554D0C6Q33426377-5145BE93-D2D4-4995-80B7-776AEA0AEB39Q33443111-76774910-6CCE-43F5-AEC7-BFAD03D2C5DCQ34377532-2CBCF67D-AC51-46B9-B218-8BCFB607E578Q37439562-696AD3FC-4ED1-4924-B5AC-081378EC12F7Q38128303-F333FCDC-7E7D-4425-A100-B37703D77CA4Q39677665-313202FD-E19A-4CB0-B5C8-C94835DB8855Q45779657-296BD7AD-FA5B-48B1-9DB9-428DC00ED5D8Q49497239-901D80F9-8B73-4157-A84D-298A5A2EDD3EQ54940305-07954B12-A752-476E-BD7D-94286000BB04Q55287154-760DAC5B-88EF-4D4C-B0FF-E455A9468119Q58481395-BE3D241D-0DA5-4177-B185-087DE0F2F57E
P2860
Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@ast
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@en
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@nl
type
label
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@ast
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@en
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@nl
prefLabel
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@ast
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@en
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@nl
P2093
P1476
Recovery and half-life of von ...... otic thrombocytopenic purpura.
@en
P2093
P577
1999-01-01T00:00:00Z